Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex vs Bevacizumab for DME in Cataract Surgery
NCT04067856Withdrawn
- Sponsor
- The Lundquist Institute
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
01
Overview
Randomised, single-blind trial of ozurdex in diabetic macular edema (DME) (2 arms), sponsored by The Lundquist Institute. Primary endpoint: Final Visual Acuity at 6 months. Planned start Jan 2020; status: withdrawn.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04067856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067856.